Bengaluru, November 12, 2021: HealthCare Global Enterprises Limited (“HCG”), the leader in India in speciality healthcare services focused on oncology and fertility today announced its financial results for the quarter (“Q2”) and six months ended September 30, 2021. Highlights for the quarter ended September 30th, 2021
Consolidated Income from Operations (“Revenue”) was INR 3,520 mn as compared to INR 2,479 mn in the corresponding quarter of the previous year, reflecting year-on-year growth of 42.0%.
Consolidated Profit Before Depreciation and Amortization, Finance Costs, Exceptional Items and Taxes (“EBITDA”) was INR 650 mn, as compared to INR 340 mn in the corresponding quarter of the previous year, a growth of 91.1% year-on-year and 19.0% quarter-on-quarter.
Consolidated Profit Before Other Income, Depreciation, and Amortization, Finance Costs, Exceptional Items and Taxes (“Operating EBITDA”), was INR 617 mn, as compared to INR 300 mn in the corresponding quarter of the previous year, a growth of 105.7% year-on-year and 20.5% quarter-on-quarter
Operating EBITDA for Existing centers was INR 598 mn, a growth of 81.7% year-on-year and 12.4% quarter-on-quarter, reflecting an Operating EBITDA margin of 21.9%
Operating EBITDA from New centers was INR 19 mn, as compared to the loss of INR 29 mn in the corresponding quarter of the previous year and loss of INR 19 mn in the previous quarter
Consolidated Profit after Taxes and Minority Interest (“PAT”) was a profit of INR 1,031 mn, as compared to the loss of INR 223 mn in the corresponding quarter of the previous year
| Period ended Sep’21 | Q2-FY22 | Q2-FY21 | Growth (y-o-y) |
| Income from Operations | 3,520 | 2,479 | 42.0% |
| EBITDA (1) EBITDA margin (%) | 650 18.5% | 340 13.7% | 91.1% |
| Operating EBITDA (2) Op. EBITDA margin (%) | 617 17.5% | 300 12.1% | 105.7% |
| PBT (3) PBT margin % | 1419 40.3% | (323) -13.0% | NM |
| PAT (4) PAT margin % | 1031 29.3% | (223) -9.0% | NM |
| Earnings per share (EPS) | 8.22 | (1.94) | NM |
Important Announcement – EasyShiksha has now started Online Internship Program “Ab India Sikhega Ghar Se”
Business Updates for Q2 FY22
Record performance with ‘all-time high’ operating financials delivered across the business:
o Highest ever monthly and quarterly Revenue and EBITDA delivered during the quarter
o Strong sequential & yearly revenue growth on the back of higher footfalls
HCG New centers continued their scale-up trajectory:
o Strong revenue growth of 57.9% y-o-y and 10.1%q-o-q
o Recorded positive EBITDA with several centers witnessing a turnaround in EBITDA (unit level)
Several regions delivered double-digit revenue growth on a sequential basis on the back of gradual unlocking
of the economy
o Maharashtra upsurge continued across all centers and delivered 17.5% revenue growth q-o-q
o East India witnessed a continuance in its growth path with 20.1% revenue growth q-o-q
o North India recorded high growth of 42.1% q-o-q
Other highlights
o Milann revenues grew by 56.9% y-o-y and our digital campaigns contributed to this
o ICRA has upgraded the credit rating of our Company to A plus (stable) from A negative (stable)
Commenting on the results, Dr. B.S. Ajaikumar, Executive Chairman, HealthCare Global Enterprises Ltd.
said, “At HCG, we believe in patient-centric care and focus on accessible oncological services, advanced
treatments, and high-quality care and outcomes. Over the years, we have emerged as a responsible brand,
earning the trust of thousands of patients and the admiration of the community. Our focus on advanced technology,
our ability to deliver exceptional clinical outcomes, and our team of dedicated specialists equip us with capabilities
to further the oncology care continuum while emerging as a pioneer and leader in oncology.
The Company has turned in industry-leading revenue growth this quarter, which is also backed by improving
profitability, especially among the new centers that have not yet reached the mature stage of operations. The
growth opportunities ahead of us in the domestic business is quite strong and we are also seeing a turnaround
in the number of international patients visiting our centers with the easing of travel restrictions. Milaan, our
fertility center has also performed very well with a growth of 57% on the back of a new leadership team under
Shailesh Guntu aided by our focus on digital outreach which is delivering us the desired results.
Overall, HCG under the dynamic leadership of Raj Gore, our CEO, is positioned very uniquely with a strong
pipeline as well as a de-levered balance sheet to deliver superior growth and profitability but with a clear focus
on tangible outcomes for all our stakeholders, most important of which are our patients for whom positive
outcomes from the disease are the best return.”
Top Courses in Software Engineering
More Courses With Certification
Mr. Raj Gore, CEO HealthCare Global Enterprises Ltd., added, “We continued with the momentum that we
had built up in the first quarter of this fiscal with a strong performance across all operating metrics in the
current quarter. We delivered our highest revenue and EBITDA for any quarter ever in our history. I would like to
highlight that over the last 3 quarters, we have consistently reported our highest revenue. What is heartening is
that the Q2 core revenues, excluding COVID and vaccination business, are also the highest ever recorded in our
history.
The growth in revenue has also been matched by a corresponding growth in profitability margins. We closed the
second quarter with our highest ever EBITDA at Rs. 65 cr. with 1.6% margin expansion over the previous
quarter. This is also the first quarter after 13 quarters where our PAT is back in the positive territory. A direct
impact of the improving financials has been the generation of free cash flow over the last two quarters.
The result showcases our entire team’s focus on driving growth and operational efficiencies which we are
confident of continuing in the quarters to come.”
About HCG Enterprises Ltd.
HealthCare Global Enterprises Ltd. (HCG), headquartered in Bengaluru, is the largest provider of cancer care in India. Through its network of 22 comprehensive cancer centers across India and Africa, HCG has brought advanced cancer care to the doorstep of millions of people. HCG’s comprehensive cancer centers provide expertise and advanced technologies for the effective diagnosis and treatment of cancer under one roof. Under the “Milann” brand, HCG operates 7 fertility centers. Strand Life Sciences, an associate company of HCG, is a precision diagnostics company with a strong track record in bioinformatics and a pioneer of genomic testing in India. For further information, visit www.hcgel.com or contact: Company Secretary and Compliance Officer: Sunu Manuel, investors@hcgoncology.com
For Further details Contact Healthcare Global Enterprises Limited PR Team
Shipali Poojary/ Lavanya Venkatesh
Shipali.p@hcgel.com / Lavanya.v@hcgel.com
M-9964026154/ 9902242957
For more related content visit Easyshiksha and Hawkscode
Empower your team. Lead the industry
Get a subscription to a library of online courses and digital learning tools for your organization with EasyShiksha
Request NowALSO READ: Siam-hosts-17th-lecture-on-sustainable-roadmap-for-fuels-in
Get Course: Google-Adwords-for-Beginners
